Australia seems poised to gain access to potentially transformative medication for obesity: Retatrutide. The dual molecule – acting on both GLP-1 and GIP receptors – demonstrates remarkable outcomes in global studies, indicating considerable decreases in BMI. While approval hasn't occurred with A